TruSight Oncology 500 Clinical Genomics Laboratory Services - Clinical Report (with interpretation)

TruSight Oncology 500 Clinical Genomic Laboratory Services offers comprehensive tumor profiling via an enrichment-based targeted next- generation sequencing panel which covers 523 genes associated with common solid tumors. The assay is compatible with formalin-fixed paraffin-embedded (FFPE) samples and is capable of performing simultaneous analysis of both RNA and DNA from a single sample covering a wide range of genes and variant types. The panel targets all coding exons per the current RefSeq database in 523 genesTruSight™ Oncology 500 Clinical Genomic Lab Services offers comprehensive tumor profiling via an enrichment-based targeted next-generation sequencing panel which that covers 523 genes associated with common solid tumors. The assay is compatible with formalin-fixed paraffin-embedded (FFPE) samples and is capable of performing simultaneous analysis of both RNA and DNA from a single sample covering a wide range of genes and variant types. The panel targets all coding exons per the current RefSeq database in 523 genes. The content of the panel includes 523 genes which assess multiple variant types including small nucleotide variants (SNVs), indels, CNVs, splice variants, fusions, and emerging immunotherapy biomarkers that rely on analysis of multiple genomic loci, such as tumor mutational burden (TMB) and microsatellite instability (MSI). Data is presented as a VCF file that meets all quality thresholds established by the Illumina Clinical Genomics Services Laboratory. The content of the panel includes 523 genes for single nucleotide variant (SNV) and indel detection and 55 genes for fusions and splice variants detection. Data is presented as a VCF file that meets all quality thresholds established by the Illumina Clinical Genomics Services Laboratory. Includes a clinical report